Evidence map›Paper›PMID 37864123›Full record

ArticleLeukemia2023

Clinical landscape of TP73 structural variants in ATL patients.

Hiroaki Hiramatsu, Rui Yokomori, Liu Shengyi, Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro and 14 more

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 2 countries.

Hiroaki HiramatsuDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Rui YokomoriCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Liu ShengyiDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Norio TanakaProject for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2724-8009
Seiichi MoriProject for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazuma KiyotaniProject for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9236-9061
Osamu GotohProject for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9363-4584
Shigeru KusumotoDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0001-9826-7616
Youko SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Centre, Fukuoka, Japan.
Asahi ItoDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ilseung ChoiDepartment of Hematology, National Hospital Organization Kyushu Cancer Centre, Fukuoka, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Michihiro HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Kisato NosakaDepartment of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID http://orcid.org/0000-0002-5935-0385
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, Nagasakin, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0002-8843-406X
Tetsuo NodaCancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroyoshi NishikawaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0001-6563-9807
Ryuzo UedaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takaomi SandaCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. csitakao@nus.edu.sg.ORCID http://orcid.org/0000-0003-1621-4954
Takashi IshidaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. itakashi@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-1060-0777
Japanese Foundation For Cancer Research · JPNagoya City University · JPNagoya University · JPImamura Hospital · JPNational Hospital Organization Kyushu Cancer Center · JPNational University of Singapore · SGKagoshima University · JPKumamoto Medical Center · JPKumamoto University Hospital · JPNagasaki University Hospital · JPOita Prefectural Hospital · JP

Funding

Japan Agency for Medical Research and Development (AMED) 20ae0101074h0001Japan Agency for Medical Research and Development (AMED) 21ae0101074h0001Japan Agency for Medical Research and Development (AMED) 22ae0101074h0001Japan Agency for Medical Research and Development (AMED) JP16cm0106301Japan Agency for Medical Research and Development (AMED) JP17cm0106301Japan Agency for Medical Research and Development (AMED) JP18cm0106301Japan Agency for Medical Research and Development (AMED) JP19cm0106301Japan Agency for Medical Research and Development (AMED) JP20cm0106301Japan Agency for Medical Research and Development (AMED) JP21cm0106301MEXT | Japan Society for the Promotion of Science (JSPS) 21K19900MEXT | Japan Society for the Promotion of Science (JSPS) 22H02918
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MicroRNAsRNA, Long NoncodingCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansTumor Protein p73MicroRNAsRNA, Long NoncodingTumor Protein p73

Identifiers

PMID37864123
PMCPMC10681890
OpenAlexW4387805559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.